Prevail Therapeutics to Present at Upcoming October Conferences
NEW YORK, Oct. 01, 2019 (GLOBE NEWSWIRE) -- Prevail Therapeutics Inc. (Nasdaq: PRVL) (“Prevail” or “the Company”), a biotechnology company developing potentially disease-modifying AAV-based gene therapies for patients with neurodegenerative disorders, today announced that management will present at three upcoming conferences in October:
- 2019 Cell & Gene Meeting on the Mesa on Thursday, October 3, 2019 at 12:00 p.m. PT in Carlsbad, CA.
- Chardan’s Annual Genetic Medicines Conference on Tuesday, October 8, 2019 at 9:00 a.m. ET in New York, NY.
- 2019 Jefferies Gene Editing Summit on Tuesday, October 8, 2019 at 1:10 p.m. ET in New York, NY.
The live webcast of all conferences will be available in the investor section of the company's website at . The webcast will be archived for 90 days following the presentation.
About Prevail Therapeutics
Prevail is a gene therapy company leveraging breakthroughs in human genetics with the goal of developing and commercializing disease-modifying AAV-based gene therapies for patients with neurodegenerative diseases. Prevail was founded by Dr. Asa Abeliovich in 2017, through a collaborative effort with The Silverstein Foundation for Parkinson’s with GBA and OrbiMed, and is headquartered in New York, NY.
Media Contact:
Katie Engleman
1AB
Investor Contact:
